Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-303P encodes a pseudogene (non-functional remnant) of the U6 small nuclear RNA gene[4][6]. U6 snRNA is a highly conserved component of spliceosomal small nuclear ribonucleoproteins (snRNPs), functioning in catalysis and regulation of pre-mRNA splicing in the spliceosome[1][3]. However, as a pseudogene, RNU6-303P does not produce a functional RNA and is not known to have biological activity or therapeutic relevance[4][6]. It shares sequence similarity with genes encoding active U6 snRNA but lacks necessary regulatory elements or sequence integrity for active transcription and function in RNA splicing[4].\n\nPseudogenes occur frequently in the human genome as byproducts of gene duplication or retrotransposition; RNU6-303P is one among many U6 small nuclear RNA pseudogenes[3][4][6]. They generally do not code for a protein or functional RNA, and their clinical or biomarker significance is unknown. Some pseudogenes have regulatory or evolutionary implications, but for RNU6-303P, no such functions have been reported[4][6][7].\n\nIt is not a receptor, enzyme, transporter, or classic drug target, and there are no drugs, mechanisms of action, or diseases associated with RNU6-303P[4][6][7]. Its presence in the genome is primarily as a non-functional genetic sequence; expression data may show transcription in certain tissues, but this is not linked to any known biological or disease function[7].\n\nRNU6-303P is a non-functional pseudogene homologous to U6 snRNA genes, with no known biological function, clinical relevance, or role in pharmacology[4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 303, pseudogene (RNU6-303P).